SWK (NASDAQ:SWKH) Trading Up 0.4% – Still a Buy?

Shares of SWK Holdings Co. (NASDAQ:SWKH) rose 0.4% during trading on Wednesday . The company traded as high as $16.25 and last traded at $15.85. Approximately 3,815 shares traded hands during trading, a decline of 64% from the average daily volume of 10,682 shares. The stock had previously closed at $15.79.

SWK Stock Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 5.06 and a quick ratio of 5.06. The company has a market capitalization of $193.85 million, a P/E ratio of 17.04 and a beta of 0.36. The company has a fifty day moving average price of $16.60 and a two-hundred day moving average price of $16.93.

Institutional Investors Weigh In On SWK

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its stake in SWK by 185.0% during the third quarter. Barclays PLC now owns 4,461 shares of the company’s stock worth $77,000 after buying an additional 2,896 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of SWK in the 2nd quarter worth about $172,000. Dimensional Fund Advisors LP raised its position in shares of SWK by 85.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 30,109 shares of the company’s stock worth $511,000 after acquiring an additional 13,892 shares in the last quarter. SkyView Investment Advisors LLC lifted its stake in shares of SWK by 7.7% in the 2nd quarter. SkyView Investment Advisors LLC now owns 31,165 shares of the company’s stock valued at $529,000 after purchasing an additional 2,234 shares during the period. Finally, Victory Capital Management Inc. bought a new stake in shares of SWK during the 3rd quarter valued at about $589,000. Institutional investors own 99.27% of the company’s stock.

SWK Company Profile

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors.